» Articles » PMID: 10821410

Sensitive High-performance Liquid Chromatographic Method for the Determination of the Lactone Form and the Lactone Plus Hydroxy-acid Forms of the New Camptothecin Derivative DX-8951 in Human Plasma Using Fluorescence Detection

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2000 May 23
PMID 10821410
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

A sensitive quantitation of the lactone form and the lactone plus hydroxy-acid forms of DX-8951, a camptothecin derivative, in human plasma has been investigated by high-performance liquid chromatography (HPLC). This assay method consisted of two analytical procedures. In Procedure I, the lactone form was collected by the stepwise separation on a C18 cartridge. In Procedure II, the lactone plus hydroxy-acid forms were collected using another batch of the plasma sample by co-elution of the two forms from a C18 cartridge with acidic solution. The hydroxy-acid form of DX-8951 was quantitated from the difference of the lactone plus hydroxy-acid forms and the lactone form. Thereafter, these pre-treated samples were assayed by HPLC under the same HPLC conditions with a spectrofluorometer and a reverse-phase ODS column. The mobile phase was acetonitrile/0.05 M potassium dihydrogen phosphate (pH 3) (18:82, v/v) at a flow-rate of 1.0 ml/min. For the assay of the lactone form and the lactone plus hydroxy-acid forms of DX-8951 in plasma, analytical method were validated over the range 0.2-50 ng/ml.

Citing Articles

A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer.

Ajani J, Takimoto C, Becerra C, Silva A, Baez L, Cohn A Invest New Drugs. 2005; 23(5):479-84.

PMID: 16133799 DOI: 10.1007/s10637-005-2907-z.


A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum.

Royce M, Rowinsky E, Hoff P, Coyle J, DeJager R, Pazdur R Invest New Drugs. 2004; 22(1):53-61.

PMID: 14707494 DOI: 10.1023/b:drug.0000006174.87869.6b.